Global Markets

BioProcess Insider State of the Industry – Live from Biotech Week Boston

Ukraine escalation, COVID drop off, cell and gene approvals, and sustainability efforts were the focus of the latest BioProcess Insider State of the Industry discussion at BPI Boston Frank Orlowski, Director of Business Development at Latham Biopharm Group, Miriam Monge, Head of Marketing Fluid Management Technologies at Sartorius, and Joseph Scott, Vice President, Supply Chain at Avid Bioservices, sat down with BioProcess Insider’s Dan Stanton to discuss the geopolitical issues affecting the biomanufacturing space. In front of a full crowd…

BioNTech heads down under to build mRNA plant

BioNTech has entered into a partnership with the State of Victoria, Australia to construct a research and manufacturing center for mRNA-based products in Melbourne. According to the German biopharma company, the center will support “discovery to delivery” of messenger RNA (mRNA) vaccines and therapies. Additionally, as part of the collaboration, BioNTech will construct a BioNTainer facility for clinical scale manufacturing of mRNA-based products and candidates. A BioNTainer is a cleanroom built from six ISO sized containers and consisting of one…

Sartorius eyes Korea opportunities through $265m investment

Sartorius has signed a land purchase agreement with the Incheon Free Economic Zone Authority (IFEZ) as it preps to bring its biomanufacturing portfolio to the robust Korean market. While Sartorius has run a sales and service office in South Korea for more than 30 years, the bioprocess vendor announced its intention to invest significantly in manufacturing operations in the region last November, pledging €270 million ($265 million) through the end of 2024. Now building is set to commence, following the…

Moderna and China at impasse over mRNA COVID vaccine

Moderna is ‘eager’ to sell its mRNA vaccine in China but balks at the idea of transferring its technology or building a manufacturing facility in the country. The conditions being imposed by China are: Moderna must sign up with a China-based partner, transferring all its technology to the China company and allowing the China company to make the drug, or the company must build a China manufacturing facility, again with a China partner, which would not involve a technology transfer.…

Japan doles out $1.5bn to strengthen vaccine manufacturing

CDMO AGC Bio is among the 17 companies selected by Japan’s Ministry of Economy, Trade, and Industry (METI) to support pandemic-ready vaccine manufacturing. As part of Japan’s fiscal 2021 budget, the ‘Biopharmaceutical Manufacturing Base Development Project for Strengthening Vaccine Production System’ invited applications from academia and industry to help secure bioproduction for future pandemics. The aim is to develop a Japan-based production network – from formulation, to fill-finish – with dual-use equipment that manufactures biopharmaceuticals that meet corporate needs during…

Boehringer Ingelheim rolls out VR training at fill-finish facilities

Boehringer Ingelheim has deployed Virtuosi, a virtual training (VR) educational platform, across three of its aseptic manufacturing sites. Virtuosi, developed by Quality Executive Partners (QxP), claims to be the “world’s first” and singular multi-language immersive training platform training platform for the pharmaceutical manufacturing operators in aseptic processing, cell and gene therapy processing, and microbiology. The VR training platform will be deployed at Boehringer Ingelheim’s Biberach and Ingelheim sites in Germany, as well as a plant in Lyon, France. According to…

The Boston cream of life sciences: All the winners from the BWB Awards

The BWB Awards celebrated the best in life sciences last night with comedian Paula Poundstone dishing out the honors. “What is biotechnology?” compere Paula Poundstone asked a packed room of biotech execs in Boston. “Does it have to do with teaching dogs to sniff for COVID?” The audience at the BWB Awards reassured her that it was slightly more extensive than that in a night where the biotech and life science communities came together to celebrate their successes over the…

CDMOs: ‘Invest in bio capacity now to meet surging demand over next 5 years’

With new targets coming from smaller biotech, there are huge opportunities for contract manufacturers that can invest today in anticipation of the demand tomorrow, says GlobalData. Ahead of his presentation at Connect to Frankfurt (opening September 28th) – a new digital platform accompanying CPHI Worldwide in Frankfurt, Germany – BioProcess Insider spoke with Quentin Horgan, associate director, Pharmaceutical Data & Analytics at analytics and consultancy firm GlobalData.   He looks ahead to what are likely to be the biggest selling…

Danaher merging Cytiva and Pall to create $7.5bn bioprocess juggernaut

Combining Cytiva and Pall will create the “broadest” and “deepest” bioprocess product portfolio in the industry, says Danaher Corporation. The decision to create ‘The Biotechnology Group’ by merging Danaher’s two bioprocess businesses was announced at the firm’s 2022 Investor & Analyst event last week. Introducing the combined entity, Danaher CEO Rainer Blair told stakeholders the decision represents the third phase in his company’s acquisitional strategy in the bioprocess space, having first acquired and “carved out” the two businesses – Pall…

MeiraGTx opens first commercial-scale gene therapy plant in Ireland

MeiraGTx has opened what it claims is the first commercial-scale gene therapy manufacturing site in Shannon, Ireland. Clinical stage gene therapy firm MeiraGTx Holdings has “unveiled” its 150,000 square-foot production facility in Shannon, Ireland with Micheál Martin, the Head of the Irish Government in attendance. “The plasmid facility has been operating actively since early this year and is now reaching a level of maturity to achieve full GMP standard and application for commercial licenses,” a spokesperson for the firm told…